A multi‐pathway perspective on protein aggregation: Implications for control of the rate and extent of amyloid formation
- 31 January 2015
- journal article
- research article
- Published by Wiley in FEBS Letters
- Vol. 589 (6) , 672-679
Abstract
The nucleation‐growth model has been used extensively for characterizing in vitro amyloid fibril formation kinetics and for simulating the relationship between amyloid and disease. In the majority of studies amyloid has been considered as the dominant, or sole, aggregation end product, with the presence of other competing non‐amyloid aggregation processes, for example amorphous aggregate formation, being largely ignored. Here, we examine possible regulatory effects that off‐pathway processes might exert on the rate and extent of amyloid formation – in particular their potential for providing false positives and negatives in the evaluation of anti‐amyloidogenic agents. Furthermore, we investigate how such competing reactions might influence the standard interpretation of amyloid aggregation as a two‐state system. We conclude by discussing our findings in terms of the general concepts of supersaturation and system metastability – providing some mechanistic insight as to how these empirical phenomena may manifest themselves in the amyloid arena.Keywords
This publication has 58 references indexed in Scilit:
- Simultaneous Measurement of Amyloid Fibril Formation by Dynamic Light Scattering and Fluorescence Reveals Complex Aggregation KineticsPLOS ONE, 2013
- Computational modeling of the relationship between amyloid and diseaseBiophysical Reviews, 2012
- Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates from their kinetics of formationProceedings of the National Academy of Sciences, 2012
- Inhibition of Amyloid FormationJournal of Molecular Biology, 2012
- Amyloidosis: Pathogenesis and New Therapeutic OptionsJournal of Clinical Oncology, 2011
- The Flavanol (−)-Epigallocatechin 3-Gallate Inhibits Amyloid Formation by Islet Amyloid Polypeptide, Disaggregates Amyloid Fibrils, and Protects Cultured Cells against IAPP-Induced ToxicityBiochemistry, 2010
- Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced ToxicityJournal of Biological Chemistry, 2010
- EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicityProceedings of the National Academy of Sciences, 2010
- A model of amyloid's role in disease based on fibril fractureBiophysical Chemistry, 2009
- Rationalization of the effects of mutations on peptide andprotein aggregation ratesNature, 2003